162997-34-4

Upstream product

• 589-87-7 1,4-bromoiodobenzene 
• 1438394-24-1 N-benzyl-1-oxo-N-(penta-3,4-dien-1-yl)indane-2-carboxamide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 163209-96-9 tert-butyl 4-(4-bromophenyl)-4-hydroxypiperidine-1-carboxylate 
• 871112-38-8 tert-butyl 4-(4-cyanophenyl)-4-hydroxypiperidine-1-carboxylate 
• 623-00-7 4-bromobenzenecarbonitrile 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 460365-08-6 4-(4-cyanophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 162997-33-3 tert-butyl 4-(4-cyanophenyl)piperidine-1-carboxylate 

Downstream Products

• 1399177-94-6 4-(1-(2,4-diethyl-5-(5-(2-methoxyethyl)-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399178-04-1 4-(1-(4-cyclobutyl-5-(5-ethoxy-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-07-4 4-(1-(4-cyclobutyl-5-(5-methoxy-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-16-5 4-(1-(4-(3,3-difluorocyclobutyl)-5-(5-ethyl-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-17-6 2-(5-(4-(4-cyanophenyl)piperidine-1-carbonyl)-2,4-dimethylphenyl)-N,N-dimethyl-1H-imidazole-5-carboxamide 
• 1399178-23-4 4-(1-(4-cyclobutyl-5-(2-(2-methoxyethyl)-1H-imidazol-5-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-30-3 4-(1-(4-cyclobutyl-5-(5-ethyl-1H-imidazol-2-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-31-4 4-(1-(4-cyclobutyl-5-(5-(methoxymethyl)-1H-imidazol-2-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-42-7 (S)-4-(1-(2,4-dimethyl-5-(5-(tetrahydrofuran-2-yl)-1H-imidazol-2-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399179-41-9 1-(3-(4-(4-cyanophenyl)piperidine-1-carbonyl)-1-methyl-1H-pyrazol-5-yl)-3-isobutylurea 
• 1399180-18-7 4-(1-(2-ethyl-4-methyl-5-(7-methyl-3,4,6,7-tetrahydropyrano[3,4-d]imidazol-2-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399175-87-1 4-(1-(4-methyl-3-(3,4,6,7-tetrahydropyrano[3,4-d]imidazol-2-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399176-23-8 4-(1-(4-methyl-3-(5-(tetrahydrofuran-3-yl)-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399181-27-1 4-(1-(5-formyl-2,4-dimethylbenzoyl)piperidin-4-yl)benzonitrile 

Relevant academic research and scientific papers

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

Imidazopyridine-based fatty acid synthase inhibitors that show anti-HCV activity and in vivo target modulation

Potent imidazopyridine-based inhibitors of fatty acid synthase (FASN) are described. The compounds are shown to have antiviral (HCV replicon) activities that track with their biochemical activities. The most potent analogue (compound 19) also inhibits rat FASN and inhibits de novo palmitate synthesis in vitro (cell-based) as well as in vivo.

Palladium-catalyzed asymmetric coupling cyclization of terminal γ-allenols with aryl iodides

A Pd-catalyzed asymmetric coupling cyclization of γ-allenols has been developed. Styrenyl derivatives can be prepared in 60-86% yields with ee values ranging from 85-92%.

Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to carboxylic acid derivatives of general formula wherein A to G are defined as in claim 1, the tautomers thereof, the stereoisomers thereof including the mixtures thereof and the addition salts thereof, particularly the physiologically acceptable salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably inhibitory effects on aggregation, and to pharmaceutical compositions containing the compounds and processes for preparing them.